Your browser is no longer supported. Please, upgrade your browser.
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
Teva Pharmaceutical Industries Limited
Index- P/E228.26 EPS (ttm)0.16 Insider Own2.70% Shs Outstand1.03B Perf Week-1.20%
Market Cap36.60B Forward P/E7.38 EPS next Y4.79 Insider Trans0.00% Shs Float1.01B Perf Month5.05%
Income68.00M PEG63.30 EPS next Q1.08 Inst Own62.50% Short Float2.07% Perf Quarter-5.63%
Sales21.90B P/S1.67 EPS this Y-96.10% Inst Trans9.14% Short Ratio1.91 Perf Half Y-30.85%
Book/sh32.84 P/B1.08 EPS next Y0.97% ROA0.10% Target Price40.57 Perf Year-37.18%
Cash/sh- P/C- EPS next 5Y3.61% ROE0.20% 52W Range31.90 - 58.05 Perf YTD-2.40%
Dividend1.36 P/FCF- EPS past 5Y-53.00% ROI2.40% 52W High-39.05% Beta0.62
Dividend %3.84% Quick Ratio0.60 Sales past 5Y3.60% Gross Margin54.10% 52W Low10.91% ATR1.13
Employees42888 Current Ratio0.90 Sales Q/Q33.00% Oper. Margin9.80% RSI (14)52.45 Volatility2.57% 2.95%
OptionableYes Debt/Eq1.07 EPS Q/Q-284.70% Profit Margin0.30% Rel Volume0.56 Prev Close35.82
ShortableYes LT Debt/Eq0.98 EarningsFeb 13 BMO Payout835.30% Avg Volume10.97M Price35.38
Recom2.30 SMA202.81% SMA500.79% SMA200-20.73% Volume6,105,439 Change-1.23%
Feb-13-17Reiterated Maxim Group Hold $41 → $40
Feb-10-17Downgrade Mizuho Buy → Neutral $40 → $27
Jan-31-17Upgrade BofA/Merrill Neutral → Buy
Jan-31-17Reiterated Barclays Equal Weight $46 → $38
Jan-20-17Downgrade JP Morgan Overweight → Neutral
Jan-09-17Downgrade Wells Fargo Outperform → Market Perform
Jan-06-17Downgrade Maxim Group Buy → Hold $49 → $41
Jan-03-17Reiterated Maxim Group Buy $52 → $49
Dec-07-16Resumed Oppenheimer Outperform
Nov-16-16Reiterated RBC Capital Mkts Outperform $58 → $51
Nov-16-16Reiterated Mizuho Neutral $45 → $40
Nov-16-16Reiterated Maxim Group Buy $72 → $52
Nov-16-16Reiterated Deutsche Bank Buy $68 → $54
Nov-16-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-16-16Downgrade Jefferies Buy → Hold $69 → $40
Nov-14-16Resumed Barclays Equal Weight $46
Nov-14-16Reiterated RBC Capital Mkts Outperform $71 → $58
Nov-07-16Downgrade BofA/Merrill Buy → Neutral
Nov-04-16Downgrade HSBC Securities Buy → Hold
Oct-31-16Upgrade Credit Suisse Neutral → Outperform
Feb-24-17 12:57PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
Feb-23-17 09:23PM  3 Stocks the Market Is Wrong About at Motley Fool
05:06PM  Teva Is Expected to See a Fall in Its Profit Margins in 2017
03:36PM  Teva Is Expected to Witness a Modest Revenue Rise in 2017
01:50PM  What Analysts Recommend for Teva Pharmaceutical in 2017
12:03PM  Billionaire Andreas Halvorsens Viking Global Cuts Losses and Dumps Southwestern Energy and Teva Pharmaceutical, Still Bullish on Bank of America at Insider Monkey
Feb-22-17 02:02PM  Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA) at Insider Monkey
08:29AM  Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Feb-21-17 12:37PM  Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug
12:26PM  Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today at Motley Fool
09:36AM  Teva Shares Get a Boost in Early Trading at Investopedia
Feb-20-17 04:40PM  Billionaire Value Investor Michael Price Adds Specialty Retailer and a REIT to Its 13F Portfolio at Insider Monkey
08:24AM  3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter at Motley Fool
07:37AM  This Keeps Driving Sanofis Growth
06:52AM  Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
Feb-17-17 10:36AM  Amgen Is Managing the Life Cycle of Its Mature Nephrology Drugs in 2017
10:35AM  If You're in Your 30s, Consider Buying These Stocks at Motley Fool
09:07AM  Parsabiv Is Expected to Boost Amgens Revenues in 2017
Feb-16-17 06:55PM  Why This Billionaire Just Shelled Out $1.1 Billion on 4 Drug Stocks at Motley Fool
12:06PM  David Tepper Invests Heavily in Pharma in 4th Quarter
09:31AM  What's Driving Lilly's (LLY) Shares after 2016 Decline?
03:25AM  Multinationals learn the limits of being big at MarketWatch
Feb-15-17 06:10PM  Teva Files 2016 Annual Report on Form 20-F Business Wire +5.36%
04:45PM  Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC
12:35PM  Teva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: 2016 By the Numbers : February 15, 2017
Feb-14-17 03:10PM  Some of biotech's biggest names have acquired this Md. company at
10:10AM  Company News for February 14, 2017
09:45AM  Teva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 14, 2017
09:45AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical Industries and Allergan Accesswire
08:55AM  Top Analyst Upgrades and Downgrades: Intuitive Surgical, Restaurant Brands, Scorpio Tankers, Teva, Under Armour, Zillow and Many More
08:20AM  Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance
12:42AM  [$$] Teva Swings to Loss on Write-Down But Beats Expectations at The Wall Street Journal
Feb-13-17 10:40PM  Teva Pharmaceutical Industries Ltd. Reports Q4 Improvement Thanks to Actavis Deal at Motley Fool +5.62%
04:01PM  Teva Maintains 2017 Guidance Despite Copaxone Patent Losses; Q4 Tops
02:53PM  Troubling Trends Seen in Teva's FY16 Results at Investopedia
01:26PM  How to Trade Monday's Most Active Stocks: BofA, Vale, Zeltiq, Teva and More
01:02PM  3 Bargain-Bin High-Yield Dividend Stocks You've Overlooked This Winter at Motley Fool
12:37PM  Teva Tries Out 'Alternative Guidance' at Bloomberg
11:35AM  Teva Said to Weigh Options for Branded Generics to Reduce Debt
11:35AM  Teva Said to Consider Options for Branded Generics Unit at Bloomberg
11:11AM  Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq
11:00AM  Teva Faces Uncertainty
10:31AM  Teva seeks CEO with pharma background to lead recovery efforts Reuters
10:27AM  Markets Climb Amid Solid Q4 Earnings
10:07AM  Teva Climbs On Upbeat Q4 Earnings, Reaffirmed Guidance at
10:02AM  Teva Claws Its Way Back With Earnings, Revenue Beat
09:39AM  Morning Movers: Verizon Falls, Teva Jumps, Hain Celestial Craters at
08:53AM  [$$] Teva Swings to Loss, But Beats Expectations at The Wall Street Journal
08:44AM  Teva Gets Actavis Boost, Q4 Results Top Estimates
08:34AM  Teva (TEVA) Tops Q4 Earnings & Sales Estimates; Shares Up
07:55AM  How Rosy Is the Outlook for Teva Pharmaceutical?
07:17AM  Market Recon: The Foundation Is Laid to Support This Rally
07:02AM  Teva Pharm Q4 profit, revenue beat expectations Reuters
06:42AM  Teva Reports Full Year and Fourth Quarter 2016 Financial Results Business Wire
05:45AM  U.S. stocks on pace to continue their run of records at MarketWatch
Feb-11-17 08:24AM  Earnings Preview: What To Expect From Teva Pharmaceutical On Monday at Forbes
Feb-10-17 06:52PM  Cramers game plan: Spotting the perfect combination for ...
06:42PM  [video]Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)
12:00PM  Is More Downside Ahead For Teva Pharmaceutical? at
08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-08-17 09:13PM  Bartosiak: Trading Teva Pharmaceutical's (TEVA) Earnings with Options
04:08PM  Gilead Sciences, Fitbit Plunge into Wednesdays 52-Week Low Club
01:21PM  [$$] Teva under police investigation in home market of Israel at Financial Times
09:57AM  Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat
09:08AM  [$$] Darkest Before the Dawn at Teva at The Wall Street Journal
08:59AM  Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
08:23AM  After Copaxone, Is Teva's Future Bleak? at Motley Fool
01:00AM  [$$] Darkest Before the Dawn at Teva at The Wall Street Journal
Feb-07-17 10:15PM  Drugmaker Teva says Israel probing kickback allegations AFP -6.29%
05:45PM  Teva Pharmaceutical CEO Erez Vigodman Departs at Investopedia
05:32PM  Teva Shares Decline After Company's CEO Exits
04:53PM  Teva shares plummet amid CEO departure and bribery reports at CNBC
04:50PM  Levin: Immigration fears will inhibit the 'best of the be...
04:09PM  Teva, Kors Stagger into Tuesdays 52-Week Low Club
04:01PM  Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives
03:29PM  Teva Pharmaceutical: 'Short-Term CEO Lease Program Continues in Earnest' at
01:45PM  Teva CEO exits in ongoing crisis of confidence at drugmaker
01:42PM  Is Teva's 4% Dividend Yield Safe?
01:00PM  Why Teva Pharmaceuticals Industries Just Lost $1.5 Billion In Market Value at Motley Fool
12:40PM  Teva says Israel probing same issues as U.S. bribery case Reuters
12:40PM  Is Tevas CEO Departure Long Overdue?
12:25PM  The Pharma Job From Hell: Low Salary to Fix a Sinking Giant
11:44AM  Teva Set to Bounce Despite Bad News at Investopedia
11:37AM  JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical at TheStreet
10:26AM  Teva Pharmaceuticals CEO Steps Down After a Series of Missteps at TheStreet
09:58AM  Teva's Dividend Should Follow Its CEO Out at Bloomberg
09:49AM  A Conversation With Teva's Interim CEO And Chair
09:43AM  Faber Report: Pharma fumbles
08:30AM  In an Ironic Twist, Generics Take Aim at Teva Pharmaceutical at Motley Fool
08:25AM  Teva, CEO part ways at
08:15AM  Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO
05:21AM  UPDATE 2-Teva Pharm's CEO Vigodman steps down amid crisis of confidence
Feb-06-17 07:30PM  PRESS DIGEST- Financial Times - Feb 7 Reuters
06:42PM  [$$] Teva CEO Erez Vigodman to Step Down at The Wall Street Journal
05:51PM  Teva Searches for a New CEO
05:41PM  Teva names interim CEO, new chairman as Vigodman steps down
05:05PM  Teva Pharma shares slide on CEO departure at MarketWatch
05:02PM  Teva Loses CEO, Leaving Investors to Guess Whats Next at Bloomberg
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company's Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The company's Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the women's health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited has collaboration arrangements with Takeda Pharmaceutical Company Limited, Procter & Gamble Company, Intel, and Regeneron Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.